Background Few studies have assessed the use of new oral anti‐diabetic agents in Asian
populations. This study assesses the efficacy and safety of saxagliptin versus placebo in …

AIM: To assess efficacy and safety of saxagliptin added to metformin versus placebo plus
metformin in Asian patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic …

Aim To assess the efficacy and safety of saxagliptin plus metformin over 24 weeks in
pharmacotherapy‐naïve Chinese patients with type 2 diabetes mellitus and inadequate …

Objective: To evaluate the efficacy and safety of once-daily saxagliptin monotherapy in
treatment-naïve patients with type 2 diabetes (T2D) and inadequate glycemic control …

BACKGROUND: Some conventional therapies for type 2 diabetes mellitus (T2DM) fail to
address the progressive nature of the disease, and as a result, they may become ineffective …

BACKGROUND: Oral antihyperglycemic drugs used to treat type 2 diabetes mellitus (T2DM)
vary in safety and tolerability. Treatment-related hypoglycemia and weight gain can …

Background: The mechanism of action of dipeptidyl peptidase-4 inhibitors, such as
saxagliptin, makes them suitable for combination therapy in type 2 diabetes mellitus (T2DM) …

Aims To evaluate the efficacy and safety of saxagliptin as add‐on therapy in adults with type
2 diabetes with inadequate glycaemic control on metformin plus a sulphonylurea. Methods …

Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the
treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination …

Aims To evaluate the safety of saxagliptin±metformin over 4 years in patients with Type 2
diabetes mellitus. Methods Drug‐naive (n= 401; study 11) or metformin‐treated (n= 743; …